OMNICELL, INC. — Director's Dealing 2022

Mar 16, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OMNICELL, Inc (OMCL)
CIK: 0000926326
Period of Report: 2022-03-14

Reporting Person: Seidelmann Scott Peter (EVP, Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-14	Common Stock	A	19040	—	Acquired	53140	Direct
2022-03-14	Common Stock	F	2235	$131.21	Disposed	50905	Direct
2022-03-16	Common Stock	S	2525	$133.11	Disposed	48380	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	43620	Direct

Footnotes

F1: Reflects performance-based restricted stock units that were previously granted on February 9, 2021 subject to the Company meeting certain stock performance objectives compared to the NASDAQ Healthcare Index, as previously reported at the target amount of 9,520 shares on Form 4 filed on February 11, 2021. On March 14, 2022 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 19,040 performance-based restricted stock units (200% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022.

F2: Reflects withholding of shares to cover taxes due in connection with the vesting of performance-based restricted stock units.

F3: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9,2021.

F4: The price reported in Column 4 is an exact price of $133.11 for all shares sold.